Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|February 1, 2001
- Pharmaceutical Executive-02-01-2001
- Volume 0
- Issue 0
Neurology's Broader Promise: An Exclusive Interview with Christopher Reeve
Author(s)Wayne Koberstein
During our conversation, Reeve pushes an even broader agenda: getting pharmaceutical companies to realize the huge market potential in spinal-cord research for a host of neurological conditions. He implores companies to put their attention, and their investment, into enterprises that are creating breakthroughs in new technologies promising wide therapeutic application.
Advertisement
Articles in this issue
over 25 years ago
The Top Ten Marketing Challenges in Neurologyover 25 years ago
A Right to Dreamover 25 years ago
Woman With a Mission: Pfizer's Lisa Egbuonu-DavisAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
How Preventative Medications May Impact the Lingering Impact of COVID-19
4
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
5